
    low accrual rate
  
['colonic neoplasms']
['imatinib']

        Inclusion Criteria:

          1. Male or female aged ≥18 years

          2. Histologically proven adenocarcinoma of the colon;

          3. Completed cancer staging with CT-abdomen and CT-thorax/X-thorax according to
             hospital's standard of care;

          4. Confirmed eligibility for surgery with curative intent as deemed by the hospital's
             multidisciplinary board (MDB) review;

          5. An intratumoural gene expression profile of PDGFR-α, PDGFR-β, PDGF-C and KIT,
             indicative of the mesenchymal phenotype, according to our diagnostic RT-qPCR test
             (i.e. more than 50% chance of having the mesenchymal phenotype);

          6. Minimum of four properly stored pre-treatment biopsies for gene expression
             analysis/ELISA;

          7. WHO performance status 0 or 1;

          8. Adequate haematology status and organ function, defined as:

               -  Normal creatinine clearance (≥60 ml/min (MRDR))

               -  ALAT within 2.5x upper limit of normal (ULN)

               -  PT-INR < 1.5

               -  Leukocytes > 1,5*10^9/L; Hb > 6.0 mmol/L; platelets > 100*10^9/L

          9. Willingness and ability to comply with scheduled visits, treatment plans and
             laboratory tests;

         10. Written informed consent.

        Exclusion Criteria:

          1. The presence of synchronous distant metastases;

          2. Current hospital standard of care dictates that subject should undergo any neoadjuvant
             therapy;

          3. Concurrent participation in another clinical trial using any medicinal product, or
             participation in such a trial in the period of three months prior to the current
             trial;

          4. Women who are pregnant, plan to become pregnant or are lactating during the study or
             for up to 30 days after the last dose of imatinib;

          5. Known HIV or Hepatitis B/C infection;

          6. Known symptomatic congestive heart failure;

          7. Co-morbidity requiring concomitant treatment with drugs that act as strong inducers of
             CYP3A4 or with drugs with a narrow therapeutic range influenced by imatinib
      